Iridex expands its EyeProGPO product line to include EndoProbe Handpieces, offering preferred pricing to over 4,300 members.
Quiver AI Summary
Iridex Corporation announced the expansion of its EyeProGPO product offerings to include the EndoProbe® Handpieces, which will provide over 4,300 EyeProGPO members with preferred pricing. This addition highlights Iridex's commitment to enhancing value for ophthalmology practices, surgical centers, and hospitals across the U.S. The EndoProbe Handpieces are single-use devices designed for use with Iridex laser consoles in treating retinal disorders, available in various models and sizes, including illuminating and adjustable designs. The partnership is seen as a significant step in improving access to advanced eye care technology, with both Iridex and EyeProGPO emphasizing their dedication to supporting healthcare providers in delivering high-quality patient care.
Potential Positives
- Iridex Corporation expands its product offering with the inclusion of EndoProbe Handpieces, enhancing its portfolio for ophthalmology practices and surgery centers.
- The partnership with EyeProGPO provides over 4,300 members access to preferred pricing on EndoProbe Handpieces, potentially increasing sales and market penetration.
- This addition reflects Iridex's commitment to supporting retina specialists, strengthening its brand reputation in the medical technology field.
Potential Negatives
- While the press release announces a product expansion, it does not provide information on the expected financial impact or projected sales growth associated with the new offering, leaving stakeholders uncertain about the company's future revenue implications.
- The focus on preferred pricing for EyeProGPO members may suggest the company is competing heavily on price, which could pressure profit margins in the long run.
- The press release does not address any competitive landscape or potential challenges Iridex may face in market adoption of their new products, possibly indicating an oversight in strategic planning and market awareness.
FAQ
What is the recent expansion by Iridex Corporation?
Iridex Corporation expanded its EyeProGPO product offering to include EndoProbe® Handpieces for its members.
How many EyeProGPO members will access Iridex products?
Over 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces.
What types of devices does the EndoProbe portfolio include?
The EndoProbe portfolio includes straight, angled, stepped-angled, illuminating, and adjustable models in various sizes.
What is the goal of the Iridex and EyeProGPO partnership?
The partnership aims to provide members with expanded access to advanced eye care technology and improved patient care.
What technologies does Iridex support in vitreoretinal laser procedures?
Iridex supports technologies like the EndoProbe Handpieces and various laser consoles for retinal disorder treatments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRIX Insider Trading Activity
$IRIX insiders have traded $IRIX stock on the open market 20 times in the past 6 months. Of those trades, 20 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IRIX stock by insiders over the last 6 months:
- ROMEO R DIZON (Chief Financial Officer) has made 20 purchases buying 39,794 shares for an estimated $52,295 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IRIX Revenue
$IRIX had revenues of $11.8M in Q1 2026. This is a decrease of -0.82% from the same period in the prior year.
You can track IRIX financials on Quiver Quantitative's IRIX stock page.
You can access data on IRIX stock through the Quiver Quantitative API.
$IRIX Hedge Fund Activity
We have seen 11 institutional investors add shares of $IRIX stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DIVERSIFY WEALTH MANAGEMENT, LLC added 33,840 shares (+inf%) to their portfolio in Q1 2026, for an estimated $34,178
- XTX TOPCO LTD removed 28,494 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $28,778
- CITADEL ADVISORS LLC added 26,456 shares (+76.9%) to their portfolio in Q1 2026, for an estimated $26,720
- RENAISSANCE TECHNOLOGIES LLC added 25,067 shares (+6.7%) to their portfolio in Q1 2026, for an estimated $25,317
- GEODE CAPITAL MANAGEMENT, LLC added 24,951 shares (+18.5%) to their portfolio in Q1 2026, for an estimated $25,200
- DIVERSIFY ADVISORY SERVICES, LLC removed 19,134 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $19,325
- THOMPSON DAVIS & CO., INC. added 18,944 shares (+66.5%) to their portfolio in Q1 2026, for an estimated $19,133
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company’s line of EndoProbe ® Handpieces.
Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces, expanding the value Iridex provides to ophthalmology practices, ambulatory surgery centers, and hospitals across the United States. The addition builds on Iridex’s existing EyeProGPO product offering, which includes the Iridex PASCAL ® laser platform, IQ 532 ® and IQ 577 ® Laser Consoles, OcuLight ® TX Laser Console, Cyclo G6 ® Laser Console, and the MicroPulse P3 ® , G-Probe ® , and G-Probe Illuminate ® delivery devices.
Iridex EndoProbe Handpieces are single-use devices indicated for use with Iridex laser consoles for the treatment of retinal disorders in adult patients. The EndoProbe portfolio includes straight, angled, stepped-angled, illuminating, and adjustable models, with configurations available in 20G, 23G, and 25G, and select stepped designs that taper to 27G and 30G.
Illuminating models combine white-light illumination with laser delivery in a single handpiece, allowing simultaneous use of additional instruments. Adjustable models provide continuous fiber-optic angle adjustment to support access to the peripheral retina.
"We are proud to partner with Iridex to offer their EndoProbe Handpieces to our members," said Phil Meyer, CEO of EyeProGPO, LLC. "This partnership underscores our strong commitment to working with our outstanding vendors while providing our members with access to the latest advancements in eye care technology, empowering them to deliver the highest quality patient care."
The expanded product offering is designed to provide EyeProGPO members with preferred access to Iridex technologies used in vitreoretinal laser procedures. By adding EndoProbe Handpieces to the existing contract, Iridex and EyeProGPO further strengthen their collaboration to provide EyeProGPO members with expanded access to the Iridex retina laser portfolio.
“We are pleased to add Iridex EndoProbe Handpieces to our EyeProGPO product offering, giving members broader access to our retina laser systems and delivery devices,” said Patrick Mercer, President and CEO of Iridex. “This addition reflects Iridex’s continued commitment to supporting retina specialists and ophthalmic providers with reliable technologies that help deliver value in vitreoretinal laser treatment.”
About EyeProGPO
EyeProGPO is an ophthalmology-focused group purchasing organization dedicated to helping ophthalmology practices, ambulatory surgery centers, and hospitals by providing access to cost-effective products and services and improving operational efficiency. With over 4,300 members, EyeProGPO harnesses collective purchasing power to deliver value on ophthalmic supplies, pharmaceuticals, intraocular lenses, capital equipment, and more. Focusing on quality, innovation, and value, EyeProGPO helps its members deliver the best possible patient care.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse
®
technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at
www.iridex.com
.
MicroPulse ® , Iridex PASCAL ® , IQ 532 ® , IQ 577 ® , OcuLight ® TX, Cyclo G6 ® , MicroPulse P3 ® , G-Probe ® , and G-Probe Illuminate ® are a registered trademark of Iridex Corporation, Inc. in the United States, Europe, and other jurisdictions.
Iridex Media Contact
Joan Stauffer
[email protected]
Investor Relations Contact
Philip Taylor
[email protected]
